5Hydroxytryptamine Receptor 7 5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7 Pipeline Review, H2 2018
Summary
5Hydroxytryptamine Receptor 7 5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7 pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report 5Hydroxytryptamine Receptor 7 Pipeline Review, H2 2018, outlays comprehensive information on the 5Hydroxytryptamine Receptor 7 5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
5Hydroxytryptamine Receptor 7 5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7 5HT7 receptor is a member of the GPCR superfamily and it is activated by the serotonin 5HT. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It plays an important role in autistic disorder and other neuropsychiatric disorders.
The molecules developed by companies in PreRegistration, Phase II, Phase I and Preclinical stages are 2, 2, 1 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders, Male Health, Respiratory and Women's Health which include indications Bipolar Disorder Manic Depression, Autism, Anxiety Disorders, Cognitive Disorders, Major Depressive Disorder, Psychiatric Disorders, Schizophrenia, Attention Deficit Hyperactivity Disorder ADHD, Female Sexual Dysfunction, Fragile X Syndrome, Idiopathic Pulmonary Fibrosis, Inflammatory Pain, Male Sexual Dysfunction, Migraine, Neuropathic Pain Neuralgia, Psychosis, Pulmonary Arterial Hypertension, Schizoaffective Disorder, Sleep Disorders and Social Anxiety Disorders SAD.
Furthermore, this report also reviews key players involved in 5Hydroxytryptamine Receptor 7 5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for 5Hydroxytryptamine Receptor 7 5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7
The report reviews 5Hydroxytryptamine Receptor 7 5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in 5Hydroxytryptamine Receptor 7 5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7 targeted therapeutics and enlists all their major and minor projects
The report assesses 5Hydroxytryptamine Receptor 7 5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to 5Hydroxytryptamine Receptor 7 5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for 5Hydroxytryptamine Receptor 7 5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding 5Hydroxytryptamine Receptor 7 5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope